Your session is about to expire
Risperdal vs Abilify
Introduction
For patients with schizophrenia, bipolar disorder, or autism, certain drugs that alter the concentrations of compounds in the brain that are linked to mood and perception, called neurotransmitters, can help in managing symptoms and improving quality of life. Risperdal and Abilify are two such drugs that are prescribed for these conditions. They each impact different neurotransmitters in the brain, but both have effects in patients with these disorders. Risperdal is a type of atypical antipsychotic that works by altering the activity of certain natural substances in the brain, mainly serotonin and dopamine. On the other hand, Abilify, also an atypical antipsychotic, works on the neurotransmitters dopamine and serotonin, but it has a unique mechanism of action in that it can enhance dopamine and serotonin signaling where it's too low, and reduce signaling where it's too high.
Risperdal vs Abilify Side By Side
| Attribute | Risperdal | Abilify |
|---|---|---|
| Brand Name | Risperdal | Abilify |
| Contraindications | Increased risk of death in older people with dementia-related psychosis. Should not be taken with QT prolonging drugs. | Increased risk of death in older people with dementia-related psychosis. Should not be taken with QT prolonging drugs. |
| Cost | For brand name, around $600 for 60 tablets of 1 mg. Generic risperidone varies between $0.15 - $0.90 per day. | For brand name, roughly $900 for 30 tablets of 5 mg. Generic aripiprazole starts at just under a dollar a day. |
| Generic Name | Risperidone | Aripiprazole |
| Most Serious Side Effect | Neuroleptic Malignant Syndrome (NMS), severe nervous system reaction, vision changes, heart problems, low sodium levels in the body. | Allergic reactions, changes in mood or mental state, seizures, confusion, vision changes, irregular or fast heartbeats, signs of a manic episode. |
| Severe Drug Interactions | QT prolonging drugs. | QT prolonging drugs. |
| Typical Dose | 1–6 mg/day for adults, starting at 0.5 mg/day for children and adolescents. | 10–15 mg/day, adjustable within 5-30 mg/day. |
What is Risperdal?
Risperidone (the generic name for Risperdal) is an atypical antipsychotic that was a significant development following the first class of antipsychotic drugs known as typical antipsychotics. Risperidone was first approved by the FDA in 1993. Risperdal works by controlling the levels of dopamine and serotonin in the brain, effectively "modulating" their activity. It is prescribed for the treatment of conditions like schizophrenia, bipolar disorder, and irritability associated with autistic disorder. Risperdal has a balancing effect on dopamine and serotonin, which results in it having fewer side effects than other antipsychotics that have stronger effects on these two neurotransmitters. On the other hand, Aripiprazole (the generic name for Abilify) is another atypical antipsychotic that was approved by the FDA in 2002. Similar to Risperdal, Abilify also works by modulating the activity of dopamine and serotonin in the brain, but it is known for its unique 'dopamine stabilizer' effect, which allows it to either enhance or reduce dopamine activity based on the brain's current levels. This results in Abilify having a different side effect profile and potentially being suitable for patients who do not respond well to Risperdal.
What conditions is Risperdal approved to treat?
Risperdal is approved for the treatment of several psychological disorders:
- Schizophrenia in adults and children who are at least 13 years old
- Bipolar disorder, specifically manic episodes associated with Bipolar I disorder in both adult and pediatric patients (10 to 17 years)
- Irritability associated with autistic disorder in children and adolescents aged 5–16 years.
- In combination with lithium or valproate, it's used for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder.
How does Risperdal help with these illnesses?
Risperdal works to manage symptoms of schizophrenia, bipolar disorder, and autism by adjusting the levels of dopamine and serotonin in the brain. It does this by blocking the receptors in the brain that these chemicals would normally bind to, thereby reducing their effects. Dopamine and serotonin are neurotransmitters, chemicals that act as messengers in the brain and throughout the body, that play an important role in mood, cognition, reward, sleep patterns, memory, and other functions. Imbalances in these neurotransmitters are thought to contribute to the symptoms of mental disorders. Therefore, by regulating dopamine and serotonin, Risperdal can limit the negative effects of these disorders and help patients manage their conditions and stabilize their moods.
On the other hand, Abilify, also a medication used to treat schizophrenia, bipolar disorder, and adjuvant treatment in depression, has a slightly different mechanism. It works as a partial agonist at dopamine D2 and serotonin 5HT1A receptors, and as an antagonist at serotonin 5HT2A receptors. This means that it can both enhance and inhibit dopamine and serotonin activity, depending on the circumstances, leading to a more balanced neurotransmitter environment. This unique mechanism of action might be beneficial in patients who do not respond adequately to other treatments.
What is Abilify?
Abilify, the brand name for aripiprazole, is an atypical antipsychotic and partial dopamine agonist. It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters). Aripiprazole was first approved by the FDA in 2002 and has since been used as an adjunctive treatment to antidepressants for major depressive disorder. Unlike other typical antipsychotics, Abilify does not fully block dopamine receptors; instead it stabilizes their activity. This unique mechanism can make its side-effect profile different from that of other antipsychotics such as Risperdal (risperidone), particularly with less likelihood of causing weight gain or metabolic syndrome. Also noteworthy is that aripiprazole doesn't cause prolactin elevation - a common side effect seen with risperidone which may lead to sexual dysfunction or menstrual irregularities. The effects on dopamine regulation can be beneficial for treating conditions like schizophrenia and bipolar disorder, especially in patients who do not respond well to 'typical' antipsychotic drugs such as Risperdal.
What conditions is Abilify approved to treat?
Abilify, also known by its generic name aripiprazole, is approved by the FDA for treatment of several disorders including:
- Schizophrenia
- Bipolar Disorder
- Major depressive disorder (as an adjunct to antidepressants)
- Irritability associated with autistic disorder in pediatric patients.
Its diverse range of applications makes it a versatile tool in managing psychiatric conditions.
How does Abilify help with these illnesses?
Dopamine, a neurotransmitter that influences various functions in the body such as mood regulation and reward-driven learning, has been linked to psychiatric conditions like schizophrenia and bipolar disorder. Abilify operates by modulating the activity of dopamine in the brain. It is classified as a partial dopamine agonist, which means it both stimulates and blocks dopamine receptors depending on their state of activation. This unique mechanism makes Abilify effective for managing symptoms associated with these disorders. Similar to Wellbutrin's relation to Prozac, Abilify can be an alternative or adjunctive treatment when patients do not respond well to other typical antipsychotics like Risperdal; or come with side effects patient cannot tolerate.
How effective are both Risperdal and Abilify?
Both risperidone (Risperdal) and aripiprazole (Abilify) have well-established histories of success in managing symptoms of psychiatric disorders, including schizophrenia and bipolar disorder. Risperidone was initially approved by the FDA in 1993, and aripiprazole followed a decade later in 2002. These two atypical antipsychotics have different mechanisms of action, which may make one more suitable than the other for certain patients.
Risperidone and aripiprazole have been directly compared in several clinical trials. In a 2002 study, both drugs were found to be equally effective in treating symptoms of schizophrenia, with similar safety profiles. Patients receiving either drug showed significant improvements in their symptoms, with no significant differences between the two treatment groups. In another study from 2007, aripiprazole was found to be associated with fewer side effects relating to metabolism, such as weight gain and changes in glucose and cholesterol levels, compared to risperidone.
A 2011 meta-analysis of studies on risperidone showed that it is effective in managing symptoms of schizophrenia and bipolar disorder, and that its side effect profile is generally favorable compared to many other antipsychotics. The same study found that risperidone is well-tolerated by most patient populations. The optimal dosage of risperidone is typically between 4 and 6 mg/day, and it has also been found to reduce suicidal ideation and behavior in some patients.
Aripiprazole, on the other hand, has been shown in a 2016 review and meta-analysis to be as effective as other common antipsychotics in managing psychiatric symptoms, but with a lower risk of metabolic side effects. Aripiprazole is typically considered a first- or second-line treatment option, meaning it is often prescribed early in the course of treatment. Most research on aripiprazole has shown it to be effective as a stand-alone treatment, although it is sometimes used in combination with other medications. Due to its unique pharmacology, aripiprazole may be an optimal treatment for patients who have not responded well to other antipsychotics or who need to avoid certain side effects.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Risperdal typically prescribed?
Oral dosages of Risperdal range from 1–6 mg/day, however, studies have indicated that doses as low as 0.5 mg/day can be effective in treating certain disorders like schizophrenia or bipolar disorder. In children and adolescents, the dosage may start at 0.5 mg/day depending on their weight and the condition being treated. Dosage can be increased after a few weeks if there is no response, but under careful medical supervision. The maximum dosage that should not be exceeded in any case is 16 mg/day for adults and varies for children based on their weight and age.
At what dose is Abilify typically prescribed?
Abilify treatment is generally started at a dosage of 10–15 mg/day. The dose can then be adjusted within the range of 5-30 mg/day, depending on individual patient response and tolerability. These doses may be taken once daily without regard to meals. However, in some cases, your healthcare provider may divide the total daily dose into two or more smaller doses per day. Maximum dose should not exceed 30 mg/day which may be considered if there is no significant clinical improvement after several weeks of treatment at lower dosages.
What are the most common side effects for Risperdal?
Some of the more common side effects of Risperdal (risperidone) include:
- Drowsiness, sleepiness or somnolence
- Dizziness
- Restlessness
- Difficulty falling asleep or staying asleep (insomnia)
- Nausea, vomiting, upset stomach, diarrhea, constipation
- Heartburn
- Dry mouth
- Increased saliva production
- Increased appetite and weight gain
- Decrease in sexual ability or desire
- Late or missed menstrual periods
- Unusual secretion of milk in women from the breasts
- Breast enlargement in men
- Changes in vision
Meanwhile, some of the more common side effects of Abilify (aripiprazole) include:
- Nausea
- Vomiting
- Constipation
- Headache
- Dizziness
- An uneasy feeling of restlessness or needing to move (akathisia)
- Anxiety
- Insomnia
- Drowsiness
- Increased saliva or drooling
- Lightheadedness or fainting when rising too quickly from a sitting or lying position
- Weight gain
- Uncontrollable movements, like tremors or shaking (tardive dyskinesia)
- Rash or allergic reactions
- Difficulty swallowing
It is important to note that these medications may affect individuals differently, and this is not an exhaustive list of potential side effects. Always consult with a healthcare provider for a comprehensive understanding of possible side effects.
Are there any potential serious side effects for Risperdal?
While both Risperdal and Abilify are used to treat similar conditions, they can have different side effects. With Risperdal, some of the serious side effects can include:
- Increased thoughts about suicide or self-harm, particularly in young adults and teenagers
- Signs of allergic reaction such as hives, difficult breathing, swelling in your face or throat
- Vision changes, such as blurred vision, eye pain or swelling, or seeing halos around lights
- Heart problems, including fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness
- Low sodium levels in the body - symptoms might include headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady
- Severe nervous system reaction - very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, tremors, feeling like you might pass out.
- Any symptoms of Neuroleptic Malignant Syndrome (NMS): high fever, stiff muscles, confusion, sweating, changes in pulse, heart rate, and blood pressure
With Abilify, the side effects are similar, but there are some differences. The medication can also cause:
- Weight gain
- Increased blood sugar levels, which can lead to or worsen diabetes
- Unusual urges, such as compulsive gambling or sexual urges
If you experience any of these symptoms after taking Risperdal or Abilify, contact your healthcare provider immediately.
What are the most common side effects for Abilify?
Abilify may potentially cause some of the following side effects:
- Nausea, vomiting, changes in appetite
- Constipation
- Headache or dizziness
- Feeling anxious or nervous
- Sleep problems (insomnia)
- Weight gain
- Blurred vision
- Dry mouth, stuffy nose
- Increased salivation or drooling
-Fast heartbeat
-Sweating, feeling hot and restless
-Tremors, muscle stiffness
-Nervousness and agitation.
Please note that while these are potential side effects, not every individual will experience them. It's essential to discuss any concerns with your healthcare provider before starting a new medication.
Are there any potential serious side effects for Abilify?
Abilify, just like any medication, can cause side effects. Some of these can be quite serious, including:
- Allergic reactions, which may present as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat
- Changes in mood or mental state, such as feeling unusually happy, irritable, or having suicidal thoughts
- Seizures or convulsions
- Confusion or trouble concentrating
- Vision changes, such as blurred vision or trouble focusing
- Irregular or fast heartbeats
- Signs of a manic episode, like having racing thoughts, increased energy, decreased need for sleep, reckless behavior, or finding that you're talking more than usual.
If you notice any of these symptoms, it's important to seek medical attention immediately.
Contraindications for Risperdal and Abilify?
Both Risperdal and Abilify, along with other antipsychotic medications, may increase the risk of death in older people who have lost touch with reality due to confusion or memory loss (dementia). If you notice worsening symptoms, including suicidal thoughts or behavior while on either medication, please seek immediate medical attention.
Neither Risperdal nor Abilify should be taken if you are taking, or have recently been taking drugs that interfere with your heart rhythm (QT prolonging drugs). Always inform your physician about all the medications you are currently using; QT prolonging drugs will require a period of clearing from the system to prevent potentially life-threatening interactions with Risperdal and Abilify.
How much do Risperdal and Abilify cost?
For the brand name versions of these drugs:
- The price for 60 tablets of Risperdal (1 mg) averages around $600, which works out to between $10–20/day, depending on your dose.
- The price for 30 tablets of Abilify (5 mg) is roughly $900, which calculates to approximately $30/day.
Thus, if you are in the higher dosage range for Risperdal (i.e., 6 mg/day or more), then branded Abilify might be less expensive on a per-day treatment basis. However, it's crucial to understand that cost should not be the primary factor when deciding which drug is best suited to your needs.
As for their generic counterparts:
- Generic risperidone can be obtained in packs starting from 20 pills and above; the approximate daily costs vary between $0.15 - $0.90 based on whether you're taking doses ranging from 1mg up to potentially as high as 6mg.
- Aripiprazole comes in packages varying from about ten up to hundreds of capsules with each dose being at least 2mg; this means prices start at just under a dollar a day and may rise depending upon specific quantities and dosing requirements.
Popularity of Risperdal and Abilify
Risperidone, available in generic form and under the brand name Risperdal, was estimated to have been prescribed to about 2.8 million people in the US in 2020. Risperidone accounted for around 30% of second-generation antipsychotic prescriptions in the US. It's commonly used for the treatment of schizophrenia, bipolar disorder, and irritability associated with autism. The prevalence of Risperidone has been generally steady over the last decade.
Aripiprazole, including brand versions such as Abilify, was prescribed to 3.9 million people in the USA in 2020. In the US, aripiprazole accounts for just under 40% of second-generation antipsychotic prescriptions. It's used for similar indications as risperidone, including schizophrenia, bipolar disorder, and as an adjunctive treatment for major depressive disorder. The prevalence of aripiprazole has been increasing over the last 10 years, potentially due to its slightly better side effect profile compared to risperidone.
Conclusion
Both Risperdal (risperidone) and Abilify (aripiprazole) are widely used in the treatment of psychiatric conditions like schizophrenia, bipolar disorder, and irritability associated with autistic disorder. They have a well-established efficacy record backed by numerous clinical studies indicating that they are more effective than placebo treatments. In some cases, these drugs may be combined for optimal therapeutic effect but this should be carefully assessed by a physician as they can interact with each other.
Risperdal predominantly works by blocking dopamine receptors while Abilify acts primarily as a partial agonist at dopamine receptors; hence their usage tends to vary based on patient symptoms and response to therapy. Risperdal is often desired when there's need for stronger control of manic symptoms or aggression, whereas Abilify might be preferred where risk of extrapyramidal side effects such as tremor and stiffness needs mitigation.
Both drugs are available in generic form which represents significant cost savings especially for patients who must pay out of pocket. Both Risperdal and Abilify could require an adjustment period meaning that effects might not be noticeable right away.
The side effect profiles between the two drugs differ somewhat: both generally being well-tolerated but risperidone has been associated more frequently with weight gain and metabolic issues such as elevated blood sugar levels compared to aripiprazole. For both medications, patients must closely monitor their mental health status particularly during initiation phase of treatment, reporting any worsening psychiatric symptoms or emergence of suicidal thoughts immediately.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Gründer, G., Kungel, M., Ebrecht, M., Göröcs, T., & Modell, S. (2006, February). Aripiprazole: Pharmacodynamics of a Dopamine Partial Agonist for the Treatment of Schizophrenia. Pharmacopsychiatry. Georg Thieme Verlag KG.http://doi.org/10.1055/s-2006-931485
- Bergmann, F., Zacher, A., Nass, A., Urban, R., Werner, C., Spevakné-Göröcs, T., … Modell, S. (2009, May). Psychosocial Functioning in Patients with Schizophrenia Treated with Aripiprazole – an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study. Pharmacopsychiatry. Georg Thieme Verlag KG.http://doi.org/10.1055/s-0028-1112129
- Ayatollahi, Z. S., Shayganfard, M., Jamilian, H., & Alaghmand, A. (2022, January 31). Comparing the efficacy of aripiprazole as an add-on to valproate with other second-generation antipsychotics in acute mania symptoms in manic patients in Iran. International Journal of Psychiatry in Clinical Practice. Informa UK Limited.http://doi.org/10.1080/13651501.2022.2030758
- Scott, L. J., & Dhillon, S. (2008). Spotlight on Risperidone in Irritability Associated with Autistic??Disorder in Children and??Adolescents???. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00023210-200822030-00006
- Croxtall, J. D. (2012, February). Aripiprazole. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11208400-000000000-00000
- Kumar P.B, S., Pandey, R. S., Thirthalli, J., Kumar P.T, S., & Kumar C, N. (2017, November 14). A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. Current Neuropharmacology. Bentham Science Publishers Ltd.http://doi.org/10.2174/1570159x15666170113100611
- Williams, R. (2001, April 15). Optimal Dosing With Risperidone. The Journal of Clinical Psychiatry. Physicians Postgraduate Press, Inc.http://doi.org/10.4088/jcp.v62n0411
- Chung M.D., Y.-C., & Eun M.D., H.-B. (1998, July). Hyperprolactinaemia induced by risperidone. The International Journal of Neuropsychopharmacology. Oxford University Press (OUP).http://doi.org/10.1017/s1461145798001011
- Foster, P. D., Camacho, X., Vigod, S., Yao, Z., Juurlink, D. N., Paterson, J. M., … Gomes, T. (2016, June 7). Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study. CMAJ Open. CMA Joule Inc.http://doi.org/10.9778/cmajo.20150095